^
    11ms
    Intratumoral or Subcutaneous MK-2118, a Non-Cyclic Dinucleotide STING Agonist, With or Without Pembrolizumab for Advanced or Metastatic Solid Tumors or Lymphomas. (PubMed, Clin Cancer Res)
    IT MK-2118 ± pembrolizumab and SC MK-2118 plus pembrolizumab had manageable toxicity and limited antitumor activity. IT but not SC administration demonstrated systemic immune effects.
    Journal • PD(L)-1 Biomarker
    |
    IL6 (Interleukin 6) • STING (stimulator of interferon response cGAMP interactor 1)
    |
    Keytruda (pembrolizumab) • MK-2118
    over1year
    Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001) (clinicaltrials.gov)
    P1, N=140, Terminated, Merck Sharp & Dohme LLC | Completed --> Terminated; Business Reasons
    Trial termination • Combination therapy • Metastases
    |
    CD4 (CD4 Molecule)
    |
    Keytruda (pembrolizumab) • MK-2118
    almost3years
    Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001) (clinicaltrials.gov)
    P1, N=140, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
    Trial completion • Combination therapy • Metastases
    |
    CD4 (CD4 Molecule)
    |
    Keytruda (pembrolizumab) • MK-2118
    3years
    Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001) (clinicaltrials.gov)
    P1, N=160, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: May 2023 --> Jan 2023 | Trial primary completion date: May 2023 --> Jan 2023
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    CD4 (CD4 Molecule)
    |
    Keytruda (pembrolizumab) • MK-2118
    over3years
    Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001) (clinicaltrials.gov)
    P1, N=160, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting | Trial completion date: Oct 2022 --> May 2023 | Trial primary completion date: Oct 2022 --> May 2023
    Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy
    |
    CD4 (CD4 Molecule)
    |
    Keytruda (pembrolizumab) • MK-2118
    almost4years
    Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001) (clinicaltrials.gov)
    P1, N=160, Recruiting, Merck Sharp & Dohme Corp. | Trial completion date: Jun 2022 --> Oct 2022 | Trial primary completion date: Jun 2022 --> Oct 2022
    Trial completion date • Trial primary completion date • Combination therapy
    |
    CD4 (CD4 Molecule)
    |
    Keytruda (pembrolizumab) • MK-2118